Derivatives of an FGFR inhibitor
The present disclosure relates to derivatives (e.g., hydroxyl, keto, glucuronide, sulfonic acid, and deuterated) of a Fibroblast Growth Factor Receptors (FGFR) inhibitor, including methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of FGFR mediated disease such as cancer.
1. A compound which is selected from:
3-(2,6-difluoro-3-hydroxy-5-methoxyphenyl)-1-ethyl-8-(morpholinomethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidin-2-one; and
3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-4-hydroxy-8-(morpholinomethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidin-2-one,
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , which is 3-(2,6-difluoro-3-hydroxy-5-methoxyphenyl)-1-ethyl-8-(morpholinomethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidin-2-one, or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 , which is 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-4-hydroxy-8-(morpholinomethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidin-2-one, or a pharmaceutically acceptable salt thereof.
4. A compound of Formula II:
wherein one C—H group is replaced with a C—X group, the N—H group is replaced with an N—X group, or the O—H group is replaced with an O—X group; wherein X is a group selected from:
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 4 , or a pharmaceutically acceptable salt thereof, wherein X is
6. The compound of claim 4 , or a pharmaceutically acceptable salt thereof, wherein X is
7. The compound of claim 4 , or a pharmaceutically acceptable salt thereof, wherein one C—H group is replaced with a C—X group.
8. The compound of claim 4 , or a pharmaceutically acceptable salt thereof, wherein the N—H group is replaced with an N—X group.
9. The compound of claim 4 , or a pharmaceutically acceptable salt thereof, wherein the O—H group is replaced with an O—X group.
10. The compound of claim 1 , or pharmaceutically acceptable salt thereof, which is substantially isolated.
11. A composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
12. The composition of claim 11 which is suitable for oral administration.
13. The composition of claim 11 which is suitable for intravenous administration.
14. The composition of claim 11 which is suitable for arterial administration.
15. The composition of claim 14 , wherein the arterial administration is hepatic arterial infusion.
16. A process of preparing Compound 2 having the formula:
or a salt thereof, comprising:
a) reacting Compound F1 having the formula:
with an amino protecting agent, to provide Compound F2 having the formula:
or a salt thereof, wherein P 1 is an amino protecting group;
b) reacting Compound F2 with DMF in the presence of B1, wherein B1 is a base, to provide Compound F3 having the formula:
or a salt thereof;
c) reacting Compound F3 with morpholine in the presence of RA1, wherein RA1 is a reducing agent, to provide Compound F4 having the formula:
or a salt thereof; and
d) deprotecting Compound F4 to provide Compound 2, or a salt thereof.
17. A process for preparing Compound 6 having the formula:
or a salt thereof, comprising:
a) reacting Compound F7 having the formula:
with A3, wherein A3 is a Lewis acid, and wherein P 2 is an amino protecting group, to provide Compound F6 having the formula:
or a salt thereof;
b) reacting Compound F6 with CD 3 I in the presence of B4, wherein B4 is a base, to provide Compound F5 having the formula:
or a salt thereof; and
c) deprotecting Compound F5 to provide Compound 6, or a salt thereof.
18. A compound selected from:
or a salt of any of the aforementioned.
19. A compound selected from:
or a salt of any of the aforementioned.